Nature Reviews Cancer contents June 2015 Volume 15 Number 6 pp317-381

If you are unable to see the message below, click here to view.

Advertisement
Precision Medicine Excellence  EA | Quintiles combines comprehensive genomic technologies with unmatched clinical expertise to help you identify the right pathways, biomarkers and patient populations that will enable you to better predict the long-term safety and efficacy of your products.
TABLE OF CONTENTS
June 2015 Volume 15 Number 6
Impact Factor 37.912 *	In this issue Research Highlights Reviews Perspectives Also this month  Featured article: MicroRNA biogenesis pathways in cancer Shuibin Lin & Richard I. Gregory
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Epigenome Roadmap Nature Publishing Group presents an online portal - the Epigenome Roadmap - which collects key research papers from The NIH Roadmap Epigenomics Program, complemented by thematical 'threads' to help the readers mine the wealth of available information. Access the Epigenome Roadmap for FREE at: nature.com/epigenomeroadmap Produced with exclusive support from  Illumina
RESEARCH HIGHLIGHTS Top Drug delivery: Get in there! p317 | doi:10.1038/nrc3963 Two different devices have been developed to deliver cancer drugs directly into tumours in vivo to evaluate cell penetration, drug stability and effectiveness. PDF Colorectal cancer: A circuitous way to target p53 p318 | doi:10.1038/nrc3962 Liu et al. show that the mushroom-derived toxin α-amanitin, conjugated to antibodies against a tumour-specific biomarker, might be effective therapeutically (with minimal toxicity) for tumours that have hemizygous deletions of TP53 that also encompass POLR2A. PDF Therapeutic resistance: Fibroblasts restrain drug sensitivity p318 | doi:10.1038/nrc3965 Hirata et al. used intravital imaging to characterize a surprising form of BRAF-V600E inhibitor resistance in melanoma. PDF Immunotherapy: Put your coat on! p319 | doi:10.1038/nrc3964 Tumour cells coated with immunoglobulin G are able to induce an immune response in mice that causes tumour regression. PDF Non-coding RNA: Stressed to bits p320 | doi:10.1038/nrc3966 Goodarzi et al. find that small non-coding RNAs derived from the cleavage of tRNAs under hypoxic conditions can suppress metastatic progression. PDF IN BRIEF Immunotherapy: Killer combo | Tumour immunology: Eosinophils — T cells' little helpers | Metabolism: Bacterial biofilms may feed colon cancer PDF Cancer JOBS of the week Senior Research Technician - Cancer Biology and Genetics Memorial Sloan Kettering Cancer Center (MSKCC) Postdoct Positions in Molecular Cancer Biology University of Pennsylvania Assistant / Associate Professor / Professor Division of Cancer Medicine MD Anderson Cancer Center Postdoctoral fellow in Cancer Research Georgia Regents University More Science jobs from Cancer EVENT Cancer Vaccines 16.09.15 London, UK More science events from
REVIEWS		Top
MicroRNA biogenesis pathways in cancer Shuibin Lin & Richard I. Gregory p321 | doi:10.1038/nrc3932 The microRNA (miRNA) biogenesis pathway is frequently altered in cancer, leading to global downregulation of miRNA levels in some cancer types. This Review discusses the alterations that affect miRNA biogenesis in cancer. Abstract | Full Text | PDF | Supplementary information
Hijacked in cancer: the KMT2 (MLL) family of methyltransferases Rajesh C. Rao & Yali Dou p334 | doi:10.1038/nrc3929 Histone-lysine N-methyltransferase 2 (KMT2) family proteins, initially named the mixed lineage leukaemia (MLL) family, are altered in many types of cancers beyond MLL. Inhibitors of KMT2 function are being developed and could work as therapeutics in a variety of cancer types. Abstract | Full Text | PDF
Radioimmunotherapy of human tumours Steven M. Larson, Jorge A. Carrasquillo, Nai-Kong V. Cheung & Oliver W. Press p347 | doi:10.1038/nrc3925 The modern manufacture of tumour-selective antibodies bearing tumour-killing radioactive cargo has effectively harnessed the power of the atom to safely destroy cancer cells. This Review presents fundamental concepts of chemistry, physics and biology that are essential for the effective radioimmunotherapy of human cancer. Abstract | Full Text | PDF | Supplementary information
Building better monoclonal antibody-based therapeutics George J. Weiner p361 | doi:10.1038/nrc3930 How can we improve the design of monoclonal antibodies (mAbs) to treat cancer? In this Review, George J. Weiner discusses the characteristics of mAbs that can affect their efficacy, the current approaches that use mAbs in cancer treatment and the numerous ways to enhance the potential of these mAb-based techniques. Abstract | Full Text | PDF
PERSPECTIVES		Top
TIMELINE The emerging complexity of gene fusions in cancer Fredrik Mertens, Bertil Johansson, Thoas Fioretos & Felix Mitelman p371 | doi:10.1038/nrc3947 Since the Philadelphia chromosome was discovered in 1960, studies over the past six decades have identified fusion genes, oncogenes that provide great diagnostic and therapeutic advantages because of their tumour-specific expression. This Timeline article revisits the spectrum of gene fusions in cancer and how the methods to identify them have evolved, and also discusses the implications of current, sequencing-based approaches for detection. Abstract | Full Text | PDF | Supplementary information
Advertisement
Nature Outlook: Colorectal Cancer Colorectal cancer is the world's fourth most deadly cancer, killing almost 700,000 people every year. And it is expected to become more common as more people adopt Western diets and lifestyles, which are implicated as risk factors. But research into screening, prevention and treatments is helping to fight the disease.  Access the Outlook free online for six months. Produced with support from: Hoffman-La Roche Ag and Eli Lilly & Company.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2013 Journal Citation Report (Thomson Reuters, 2014)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.